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Abstract
Telogen effluvium is one of the most common causes of alopecia. It is a scalp disorder
characterized by excessive shedding of hair. Several factors such as drugs, trauma, and
emotional and physiological stress can lead to the development of telogen effluvium. Multiple
alterations in the hair cycle have been proposed as the underlying mechanism. Telogen
effluvium can present as acute or chronic hair fall with symptoms such as trichodynia.
Diagnostic tests that can be used include hair wash test, trichogram, phototrichogram, and
scalp biopsy. In the treatment of telogen effluvium, it is essential to identify and remove the
causative factors and to use drugs such as corticosteroids, minoxidil, and novel treatments such
as CNPDA (caffeine, niacinamide, panthenol, dimethicone, and an acrylate polymer). Herein,
we discuss the presentation, diagnostic approaches, and effective treatment options available
for telogen effluvium.
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Introduction And Background
Telogen effluvium is a scalp disorder characterized by diffuse, non-scarring shedding of hair [1].
The term “telogen effluvium” was proposed to differentiate it from excessive shedding of
normal club hair. Various hypotheses are put forward regarding the pathophysiology of telogen
effluvium. Headington proposed that there are five different functional types of telogen
effluvium based on alternations in particular phases of the follicular cycle [2]. Whiting defined
chronic telogen effluvium as an idiopathic disorder [3].
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Telogen effluvium has been related to a variety of insults which can be physical, mental, or
chemical in nature [1,4].
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Review
Epidemiology
Most of the cases of telogen effluvium are subclinical; therefore, its true incidence is not clearly
known [5]. No racial predilection of the disease has been recognized and it affects both males
and females, with a higher incidence rate in females. However, it should be taken into account
that women take hair shedding problem more seriously than men and are likely overrepresented in seeking medical treatment [1]. The association of telogen effluvium with age is
unclear; however, elderly women are known to be more susceptible to acute telogen effluvium
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following fever, trauma, hemorrhage, or psychological stress [1]. Studies have reported the
incidence of telogen effluvium in children to be around 2.7% [6].

Presentation
Acute Telogen Effluvium
Acute telogen effluvium is defined as hair shedding lasting for less than six months. Generally,
hair loss occurs two to three months after the trigger exposure. In around 33% of the cases, the
cause remains unknown [2]. Acute telogen effluvium usually undergoes remission in around
95% of cases. On examination of those with resolved effluvium, there is an appearance of
shorter, re-growing frontal hair. Such hair can be seen in a large quantity using
videodermoscopy [1,7]. A variant of acute telogen effluvium is telogen gravidarum, which is
associated with pregnancy and usually occurs two to five months after childbirth [2].

Chronic Telogen Effluvium
Chronic telogen effluvium is a condition lasting for more than six months. The disorder mostly
affects middle-aged women, having a prolonged fluctuating course. The examination of the
scalp shows hair having normal thickness with signs of shorter re-growing hair in the frontal
and bitemporal areas [1].

Pathogenesis
Telogen effluvium is caused by an abnormality in the normal hair cycle, which is triggered by
numerous factors.

Normal Hair Cycle
A hair follicle has a three-phase life cycle. It consists of a growing phase (anagen), an involuting
phase (catagen), and a resting phase (telogen). The anagen phase can last for about two to five
years, and around 90% of scalp hair is in this phase [8]. The catagen phase is a much shorter
phase, lasting three to six weeks. During this phase, the hair follicles go through a process of
programmed cell death (apoptosis) [8,9]. Finally, the telogen phase lasts for around three to five
months, and 10% of the scalp hair are in this phase. During this phase, the hair shaft matures
into a club hair, which is eventually shed from the follicle. If the percentage of scalp follicles
present in the telogen phase increases, this results in excessive shedding of hair [8,9].

Mechanism of Shedding
The five proposed mechanisms by which shedding of the hair may occur in telogen effluvium
are as follows:
1. Immediate anagen release: This is due to an underlying cause. Follicles leave the anagen
phase and enter the telogen phase prematurely, leading to increased shedding two to three
months later [2].
2. Delayed anagen release: This is due to prolongation of the anagen phase resulting in heavy
telogen shedding [2].
3. Short anagen syndrome: This is due to idiopathic shortening of the anagen phase, leading to
persistent telogen effluvium. The pathogenesis behind most of the cases of chronic telogen
effluvium is considered to be the short anagen syndrome [2].
4. Immediate telogen release: This is due to the shortening of the telogen phase, resulting in a
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massive release of club hair [2].
5. Delayed telogen release: This is due to a prolonged telogen phase and a delayed transition to
anagen phase [2,10].

Causes of telogen effluvium
There are various factors that can initiate disturbance in the normal hair cycle.

Drugs
Numerous drugs can cause telogen hair loss and it usually starts after 12 weeks of dosage [2,4].
Changes in the dosage of drugs can also lead to excessive shedding [11]. Drugs that can cause
telogen effluvium include oral contraceptive pills, androgens, retinoids, beta-blockers, ACE
(angiotensin-converting enzyme) inhibitors, anticonvulsants, antidepressants, and
anticoagulants (heparin) [11].

Physiological Stress
Increased physiological stress such as surgical trauma, high fever, chronic systemic illness, and
hemorrhage can cause telogen effluvium [12]. Childbirth can also cause excessive hair to enter
the telogen phase. This hair loss, telogen gravidarum, occurs approximately three months after
childbirth [12].

Emotional Stress
The relationship between emotional stress and hair loss is ambiguous since hair loss itself is a
source of emotional stress to the patient [11].

Medical Conditions
Numerous medical disorders can lead to telogen effluvium. Both hyper- and hypothyroidism
can cause telogen effluvium, and this is reversed once the euthyroid state is achieved [13].
Chronic systemic disorders such as systemic amyloidosis, hepatic failure, chronic renal failure,
inflammatory bowel disease, and lymphoproliferative disorders can also cause telogen
effluvium [12]. It is also reported in some autoimmune diseases including dermatomyositis,
chronic infections such as HIV, and secondary syphilis. Inflammatory disorders such as psoriasis
and seborrheic dermatitis can also lead to diffuse telogen hair loss [11].

Dietary Triggers
Severe protein, fatty acid and zinc deficiency, chronic starvation, and caloric restriction can
lead to telogen effluvium [11]. Essential fatty acid deficiency leads to telogen effluvium, and
this usually occurs two to four months after insufficient intake [11,14]. Decreased body iron
stores can cause it. However, this relationship is very controversial [14]. Vitamin D is vital for
cell growth and, hence, its deficiency could also be a possible cause of it. Another cause can be
biotin deficiency but is reportedly very rarely [11,15].

Ultraviolet Light
Researchers found an increased frequency of telogen effluvium between July and October. They
hypothesized that it could be actinic effluvium, a summer effect, induced by sunlight and
ultraviolet (UV) light, manifesting in autumn [16]. Electron microscopy of hair exposed to
sunlight reveals alterations in the cellular components and damage to the hair cuticle and
cortex. Both of these mechanisms can be attributed to increased shedding of hair in the telogen
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phase; however, it is not scientifically proven yet [1].

Diagnostic considerations
Trichodynia
A major symptom of telogen effluvium is trichodynia. It presents with complaints such as
tenderness, pain, burning, itching, stinging, and diffuse alopecia [15,17].

Modified Wash Test and Hair Loss Count
The modified wash test is an office procedure that permits to identify patients with telogen
effluvium or androgenetic alopecia, and the severity of diseases. It is performed after five days
of abstention from shampooing. The patients are asked to wash and rinse their hair in a sink
covered by gauze, collect the hair, let them dry, and put them in an envelope. Afterward, the
collected hair are counted along with the percentage of vellus hair [18]. The results and possible
diagnosis are as follows:
1. Telogen effluvium: More than 100 shed hair, less than 10% vellus.
2. Androgenetic alopecia: Less than 100 shed hair, more than 10% vellus.
3. Association of telogen effluvium and androgenetic alopecia: More than 100 shed hair, more
than 10% vellus.
4. Normal or remitting telogen effluvium: Less than 100 shed hair, less than 10% vellus.

Trichogram
Trichogram is a plucking of hair in a defined area (40-60 hair). Cases of telogen effluvium show
a significant reduction of the anagen:telogen ratio. More than 25% of hair are found to be in the
telogen phase in the case of telogen effluvium [19].

Phototrichogram and TrichoScan®
This technique involves trimming the hair of a 2 sq. cm area of scalp, pictures of the same area
taken on different days, and then compared in hair density, hair growth, and rate of shedding.
Since only anagen hair would elongate it helps in the assessment of the ratio of anagen:telogen
hair. A TrichoScan is a fully computerized phototrichogram [20]. A TrichoScan is a simpler,
noninvasive, reproducible, and more sensitive than a classical trichogram and very useful in the
diagnosis of hair loss [20].

Videodermoscopy
In the case of acute telogen effluvium, videodermoscopy will show numerous short re-growing
hair with no variability of density [21].

Scalp Biopsy
It is recommended in cases where telogen loss lasts greater than six months. Performing
multiple biopsies increases the diagnostic accuracy of telogen effluvium [22]. In the case of
acute telogen effluvium, there is a normal to supernormal anagen:telogen ratio [23]. Follicular
miniaturization and peribulbar infiltrate are not found. In chronic telogen effluvium, there are
increased telogen hair, with an anagen:telogen ratio of 8:1 compared with 14:1 on normal scalp
biopsies [21].
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Management and treatment
Acute Shedding versus Chronic Shedding
Acute telogen effluvium becomes self-limited if the triggering factor is identified and removed.
Causative conditions such as scalp conditions (e.g., psoriasis, seborrheic dermatitis) should be
treated [24]. The patient’s drug history should be obtained in detail, and drugs suspected to
cause the condition should be replaced or discontinued [5]. The longer the duration of
shedding, the more probable the involvement of multiple and repetitive triggers such as
nutritional deficiencies, thyroid disease, systemic illnesses, or infections. This makes the search
for triggers more difficult and may require frequent visits [24].

Patient Education
Patient education is important in disease management. Disease correlation with triggers, and
the timing of hair loss should be explained and frustrations addressed. Hair is an important part
of the human body; the degree of psychological disability due to hair loss varies from person to
person [25].

Correcting Deficiencies
If a measurable deficiency has been found, it should be corrected. A balanced diet and stable
body weight are important. Although the use of polyphenolic compounds such as those in green
tea has been reported to improve hair loss in mice, no such controlled studies are available for
humans [26].

Minoxidil and Finasteride
The currently available FDA-approved standard drugs minoxidil and finasteride are neither
efficient catagen inhibitors nor anagen inducers [5]. Catagen-inducing drugs (e.g., betablockers, retinoids, anticoagulants, antithyroid drugs) should be avoided, and catagen-inducing
endocrine disorders (e.g., androgen disorders, thyroid disorders, abnormal prolactin levels)
should be treated [1].

Topical Corticosteroids
Topical corticosteroids are employed by dermatologists in the treatment. If the patient reports
decreasing trichodynia after the application of topical corticosteroids, it is a sign of the therapy
being effective [27].

Systemic Corticosteroids
In chronic telogen effluvium, corticosteroids can be given systematically especially if telogen
effluvium is the manifestation of underlying systemic disorder like SLE [28].

CNPDA
Davis et al. reported a novel treatment of thinning of hair. This new treatment named CNPDA
comprises a combination of caffeine, niacinamide, panthenol, dimethicone, and an acrylate
polymer. This combination leads to an increased cross-sectional area of individual terminal
scalp hair by 10% [29].

Conclusions
A thorough history, clinical examination, and laboratory investigations can aid in the diagnosis
of telogen effluvium. Acute telogen effluvium can usually be resolved by removing the
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underlying causative factors. However, the treatment of chronic telogen effluvium can be
challenging for physicians. A few treatment options are available, but standard guidelines for
therapy, frequency, and dosage of drugs need to be established.
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